Mekinist and Ocular toxicities
Result of checking the interaction of drug Mekinist and disease Ocular toxicities for safety when used together.
When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.
Consumer:Ocular toxicities, including retinal vein occlusion (RVO), retinal pigment epithelial detachment (RPED) have been reported with the use of trametinib. It is recommended to perform ophthalmological evaluation periodically and at any time a patient reports visual disturbances. Permanently discontinue treatment with trametinib in patients with documented RVO, or RPED. Withhold therapy with trametinib if RPED is diagnosed. If resolution of the RPED is documented on repeat ophthalmological evaluation within 3 weeks, resume treatment or reduce the dose or discontinue treatment if no improvement.